These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]). Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442 [TBL] [Abstract][Full Text] [Related]
5. Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy. Lamb YN Am J Cardiovasc Drugs; 2021 Jan; 21(1):113-121. PubMed ID: 33469827 [TBL] [Abstract][Full Text] [Related]
6. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy. Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059 [No Abstract] [Full Text] [Related]
7. Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy. Falk RH; Haddad M; Walker CR; Dorbala S; Cuddy SAM JACC CardioOncol; 2021 Oct; 3(4):580-586. PubMed ID: 34729530 [TBL] [Abstract][Full Text] [Related]
9. Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy. Tess DA; Maurer TS; Li Z; Bulawa C; Fleming J; Moody AT Amyloid; 2023 Jun; 30(2):208-219. PubMed ID: 36399070 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of tafamidis in transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis. Sukaina M; Rehman S; Waheed M; Shehryar M; Rasool R; Ahmed N; Ochani S; Hasibuzzaman MA Ann Med Surg (Lond); 2024 Jan; 86(1):433-438. PubMed ID: 38222729 [TBL] [Abstract][Full Text] [Related]
11. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Maurer MS; Elliott P; Merlini G; Shah SJ; Cruz MW; Flynn A; Gundapaneni B; Hahn C; Riley S; Schwartz J; Sultan MB; Rapezzi C; Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611125 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT. Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574 [TBL] [Abstract][Full Text] [Related]
13. Specific Therapy for Transthyretin Cardiac Amyloidosis: A Systematic Literature Review and Evidence-Based Recommendations. Marques N; Azevedo O; Almeida AR; Bento D; Cruz I; Correia E; Lourenço C; Lopes LR J Am Heart Assoc; 2020 Oct; 9(19):e016614. PubMed ID: 32969287 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Damy T; Garcia-Pavia P; Hanna M; Judge DP; Merlini G; Gundapaneni B; Patterson TA; Riley S; Schwartz JH; Sultan MB; Witteles R Eur J Heart Fail; 2021 Feb; 23(2):277-285. PubMed ID: 33070419 [TBL] [Abstract][Full Text] [Related]
16. Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial. Shah SJ; Fine N; Garcia-Pavia P; Klein AL; Fernandes F; Weissman NJ; Maurer MS; Boman K; Gundapaneni B; Sultan MB; Elliott P JAMA Cardiol; 2024 Jan; 9(1):25-34. PubMed ID: 37966817 [TBL] [Abstract][Full Text] [Related]
17. Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Hanna M; Damy T; Grogan M; Stewart M; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS Am J Cardiol; 2021 Feb; 141():98-105. PubMed ID: 33220323 [TBL] [Abstract][Full Text] [Related]
18. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy. Elliott P; Drachman BM; Gottlieb SS; Hoffman JE; Hummel SL; Lenihan DJ; Ebede B; Gundapaneni B; Li B; Sultan MB; Shah SJ Circ Heart Fail; 2022 Jan; 15(1):e008193. PubMed ID: 34923848 [TBL] [Abstract][Full Text] [Related]
19. Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies. Rozenbaum MH; Garcia A; Grima D; Tran D; Bhambri R; Stewart M; Li B; Heeg B; Postma M; Masri A Eur Heart J Qual Care Clin Outcomes; 2022 Aug; 8(5):529-538. PubMed ID: 33895806 [TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Kazi DS; Bellows BK; Baron SJ; Shen C; Cohen DJ; Spertus JA; Yeh RW; Arnold SV; Sperry BW; Maurer MS; Shah SJ Circulation; 2020 Apr; 141(15):1214-1224. PubMed ID: 32078382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]